Patents by Inventor Irwin D. Kuntz
Irwin D. Kuntz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7601750Abstract: Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl); inhibiting Wnt signaling.Type: GrantFiled: October 11, 2006Date of Patent: October 13, 2009Assignee: The Regents of the University of CaliforniaInventors: R. Kiplin Guy, Irwin D. Kuntz, Jose Haresco, Naoaki Fujii, Kathleen P. Novak, David Stokoe, Biao He, Liang You, Zhidong Xu, David M. Jablons
-
Patent number: 7167819Abstract: The present invention provides a fast and efficient method for determining the three-dimensional conformation of a protein. The steps of the method of the invention include: 1) formation of physical distance constraints, e.g., forming intramolecular chemical crosslinks of known size between residues of a protein; 2) enriching the number of the molecules that have intramolecular chemical crosslinks in the reaction pool, e.g., using size separation to remove proteins with intermolecular bonds; 3) exposing the enriched reaction pool to a protease that cuts the protein at specific sites to produce peptide fragments; 4) measuring the size of the peptide fragments to determine linkage sites with a certain spatial relationship in the protein; and 5)interpreting the data produced to determine spatial geometry and protein structure based on the deduced spatial relationship of the linkage sites.Type: GrantFiled: May 26, 2000Date of Patent: January 23, 2007Assignees: Chiron Corporation, The Regents of the University of CaliforniaInventors: Bradford W. Gibson, Irwin D. Kuntz, Ning Tang, Gavin Dollinger, Connie M. Oshiro, Judith C. Hempel, Eric W. Taylor, Malin Young
-
Patent number: 7141600Abstract: Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl); inhibiting Wnt signaling.Type: GrantFiled: April 15, 2004Date of Patent: November 28, 2006Assignee: The Regents of the University of CaliforniaInventors: R. Kiplin Guy, Irwin D. Kuntz, Jose Haresco, Naoaki Fujii, Kathleen P. Novak, David Stokoe, Biao He, Liang You, Zhidong Xu, David M. Jablons
-
Patent number: 7119105Abstract: The present invention relates to () non-peptide aspartyl protease inhibitors; (ii) methods for modulating the processing of an amyloid precursor protein (APP); (iii) methods for modulating the processing of a tau protein (?-protein); and (iv) methods for treating neurodegenerative diseases.Type: GrantFiled: February 5, 2004Date of Patent: October 10, 2006Assignee: The Regents of the University of CaliforniaInventors: Jonathan A. Ellman, Gary Lynch, Irwin D. Kuntz, Xiaoning Bi, Christina E. Lee, A. Geoffrey Skillman, Tasir Haque
-
Publication number: 20040157896Abstract: The present invention relates to (i) non-peptide aspartyl protease inhibitors; (ii) methods for modulating the processing of an amyloid precursor protein (APP); (iii) methods for modulating the processing of a tau protein (&tgr;-protein); and (iv) methods for treating neurodegenerative diseases.Type: ApplicationFiled: February 5, 2004Publication date: August 12, 2004Inventors: Jonathan A. Ellman, Gary Lynch, Irwin D. Kuntz, Xiaoning Bi, Christina E. Lee, A. Geoffrey Skillman, Tasir Haque
-
Publication number: 20030149038Abstract: The present invention provides methods for making compounds and methods for using the compounds to disrupt or inhibit protein-protein interactions. Also provided are pharmaceutical compositions comprising the compounds of the current invention.Type: ApplicationFiled: November 12, 2002Publication date: August 7, 2003Applicant: The Regents of the University of CaliforniaInventors: Rodney K. Guy, Irwin D. Kuntz, Felice Lu
-
Patent number: 6221877Abstract: The use of certain heterocyclic derivatives for treating parasitic protozoa infections in mammals, in particular bovine trichomoniasis and giardiasis, is disclosed.Type: GrantFiled: April 12, 2000Date of Patent: April 24, 2001Assignee: Regents of the University of CaliforniaInventors: Alex M. Aronov, Narsimha R. Munagala, Paul R. Ortiz de Montellano, Irwin D. Kuntz, Ching C. Wang
-
Patent number: 6150416Abstract: The present invention provides non-peptide cathepsin D binding compounds and methods for using such compounds in the detection, labelling and inhibition of cathepsin D.Type: GrantFiled: February 3, 1998Date of Patent: November 21, 2000Assignee: The Regents of the University of CaliforniaInventors: Ellen K. Kick, Jonathan A. Ellman, Irwin D. Kuntz, Christina E. Lee, Guangcheng Liu, Diana C. Roe, A. Geoffrey Skillman
-
Patent number: 6140368Abstract: The present invention relates to a novel class of compounds that are potent inhibitors of HIV reverse transcriptase and HIV integrase. In addition to being multienzyme inhibitors, the inventive compounds of the present invention are remarkable in at least two other respects. First, they do not appear to be toxic to cells at typical therapeutic concentrations. Second, they appear to be equally effective against mutant strains of HIV reverse transcriptase commonly found in patients who have developed resistance to current reverse transcriptase inhibitors. Because the inventive compounds show promise in combatting viral resistance and are potent inhibitors of both HIV reverse transcriptase and integrase, they are ideal candidates for use in combination with existing therapies or alone in treating AIDS or HIV infection.Type: GrantFiled: May 4, 1998Date of Patent: October 31, 2000Assignees: The Regents of the University of California, Rutgers, The University of New JerseyInventors: George L. Kenyon, Margaret Stauber, Karl Maurer, Dolan Eargle, Angelika Muscate, Andrew Leavitt, Diana C. Roe, Todd J. A. Ewing, Allan G. Skillman, Jr., Edward Arnold, Irwin D. Kuntz, Malin Young
-
Patent number: 6080791Abstract: A method of preventing and treating a viral condition caused by an enveloped virus is described, comprising using a therapeutically effective amount of a compound selected from the group consisting of a substituted hydroquinone and the corresponding benzoquinone, wherein said hydroquinone comprises a 2-R.sup.1, 3-R.sup.2 -1,4-hydroquinone where at least one of R.sup.1 and R.sup.2 include a carbon linkage to the benzene ring of the hydroquinone. Particularly useful compounds include 5,8-dihydro-5,8-methano-1,4-naphthalenediol, 1,4-naphthoquinone, 3', 6'-dihydroxybenzo-norbornane, tert-butylhydroquinone, other diols, e.g. 1,5-naphthalenediol, and alkylated diols, e.g. 4-methoxy-1-naphthol.Type: GrantFiled: July 24, 1992Date of Patent: June 27, 2000Assignees: Seres Laboratories, Inc., University of CaliforniaInventors: Dale L. Bodian, Judith M. White, Irwin D. Kuntz, Jay F. Stearns, R. Bryan Yamasaki
-
Patent number: 6075044Abstract: The use of certain heterocyclic derivatives for treating parasitic protozoa infections in mammals, in particular bovine trichomoniasis and giardiasis, is disclosed.Type: GrantFiled: July 17, 1998Date of Patent: June 13, 2000Assignee: The Regents of the University of CaliforniaInventors: Ching C. Wang, John Somoza, Jon P. Page, Ronaldus Marcellus Alphonsus Knegtel, Irwin D. Kuntz, Connie M. Oshiro, A. Geoffrey Skillman
-
Patent number: 5705333Abstract: The present invention provides novel nucleic acid mimics (termed "PENAMs") comprising a peptidic backbone and nucleotidic sidechains; the sidechains being oriented in such a way that the PENAM is homomorphous to target nucleic acids with which it can effectively hydrogen bond. Homomorphism is achieved by the incorporation of unusual sterochemical centers, including D-chiral centers and quasi-chiral centers, into the peptidic backbone. The PENAMs are useful for targeting nucleic acid sequences in order to modulate their activity in an "antisense" manner. Targeting can also be used to detect, isolate or modify target nucleic acids.Type: GrantFiled: August 5, 1994Date of Patent: January 6, 1998Assignee: The Regents of The University of CaliforniaInventors: Vibhakar J. Shah, George L. Kenyon, Irwin D. Kuntz
-
Patent number: 5583000Abstract: Non-peptide, protease-binding compounds are described as useful in the detection, labelling, and inhibition of retroviral proteases. Aryl piperidinyl derivatives and other compounds related in structure have been found to be HIV-1 and HIV-2 protease-binding compounds.Type: GrantFiled: September 16, 1993Date of Patent: December 10, 1996Assignee: The Regents of the University of CaliforniaInventors: Paul R. Ortiz de Montellano, Irwin D. Kuntz, Charles S. Craik, Paul S. Furth, Juan C. Alvarez, Patricia S. Caldera, Dianne L. DeCamp, Lilia M. Bab e, James De Voss, Rafael Salto, Zhihua Sui